Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatmentReportar como inadecuado

Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Breast Cancer Research

, 18:83

First Online: 08 August 2016Received: 12 April 2016Accepted: 25 July 2016DOI: 10.1186-s13058-016-0744-y

Cite this article as: Bourgeois-Daigneault, MC., St-Germain, L.E., Roy, D.G. et al. Breast Cancer Res 2016 18: 83. doi:10.1186-s13058-016-0744-y


BackgroundBreast cancer is the most common malignant disease amongst Western women. The lack of treatment options for patients with chemotherapy-resistant or recurrent cancers is pushing the field toward the rapid development of novel therapies. The use of oncolytic viruses is a promising approach for the treatment of disseminated diseases like breast cancer, with the first candidate recently approved by the Food and Drug Administration for use in patients. In this report, we demonstrate the compatibility of oncolytic virotherapy and chemotherapy using various murine breast cancer models. This one-two punch has been explored in the past by several groups with different viruses and drugs and was shown to be a successful approach. Our strategy is to combine Paclitaxel, one of the most common drugs used to treat patients with breast cancer, and the oncolytic Rhabdovirus Maraba-MG1, a clinical trial candidate in a study currently recruiting patients with late-stage metastatic cancer.

MethodsWe used the EMT6, 4 T1 and E0771 murine breast cancer models to evaluate in vitro and in vivo the effects of co-treatment with MG1 and Paclitaxel. Treatment-induced cytotoxicity was assessed and plaque assays, flow cytometry, microscopy and immunocytochemistry analysis were performed to quantify virus production and transgene expression. Orthotopically implanted tumors were measured during and after treatment to evaluate efficacy and Kaplan-Meier survival curves were generated.

ResultsOur data demonstrate not only the compatibility of the treatments, but also their synergistic cytopathic activity. With Paclitaxel, EMT6 and 4 T1 tumors demonstrated increased virus production both in vitro and in vivo. Our results also show that Paclitaxel does not impair the safety profile of the virus treatment. Importantly, when combined, MG1 and the drug controlled tumor growth and prolonged survival.

ConclusionsThe combination of MG1 and Paclitaxel improved efficacy in all of the breast cancer models we tested and thus is a promising alternative approach for the treatment of patients with refractory breast cancer. Our strategy has potential for rapid translation to the clinic, given the current clinical status of both agents.

KeywordsBreast Cancer Triple-negative breast cancer TNBC Oncolytic virus Rhabdovirus Maraba-MG1 Paclitaxel Viral Sensitizer Combination therapy Electronic supplementary materialThe online version of this article doi:10.1186-s13058-016-0744-y contains supplementary material, which is available to authorized users.

Download fulltext PDF

Autor: Marie-Claude Bourgeois-Daigneault - Lauren Elizabeth St-Germain - Dominic Guy Roy - Adrian Pelin - Amelia Sadie Aitken - R


Documentos relacionados